At a glance

ClinicalIndex Comparison Record

Phase 3Completed

Drug / intervention

cholestyraminedrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000594

NCT00000594Phase 3Completed

Compare CT.gov

NHLBI Type II Coronary Intervention Study

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Apr 27, 2012

In Brief

A Phase 3 clinical trial evaluating cholestyramine for Cardiovascular Diseases and 5 related conditions. Completed.

Detailed Summary

To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Hypercholesterolemia, Familial, Myocardial Infarction, Myocardial Ischemia

Countries--

Collaborators--

Timeline

Phase 3CompletedFinished

1971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Enrollment StartNov 1971

Study CompletionNov 1976

First PostedOct 1999

TodayJul 2026

First PostedOct 28, 1999

Enrollment StartNov 1, 1971

Study CompletionNov 1, 1976

TodayJul 2, 2026

Posted 26.7 years ago

Interventions

cholestyraminedrug